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Abstract
Background: Electroencephalography at hospital presentation may offer important insights regarding prognosis
that can inform understanding of cerebral malaria (CM) pathophysiology and potentially guide patient selection and
risk stratification for future clinical trials. Electroencephalogram (EEG) findings in children with CM in Uganda and
Malawi were compared and associations between admission EEG findings and outcome across this diverse popula‑
tion were assessed. Demographic, clinical and admission EEG data from Ugandan and Malawian children admitted
from 2009 to 2012 with CM were gathered, and survivors assessed for neurological abnormalities at discharge.
Results: 281 children were enrolled (Uganda n = 122, Malawi n = 159). The Malawian population was comprised
only of retinopathy positive children (versus 72.5% retinopathy positive in Uganda) and were older (4.2 versus
3.7 years; p = 0.046), had a higher HIV prevalence (9.0 versus 2.8%; p = 0.042), and worse hyperlactataemia (7.4
versus 5.2 mmol/L; p < 0.001) on admission compared to the Ugandan children. EEG findings differed between the
two groups in terms of average voltage and frequencies, reactivity, asymmetry, and the presence/absence of sleep
architecture. In univariate analyses pooling EEG and outcomes data for both sites, higher average and maximum
voltages, faster dominant frequencies, and retained reactivity were associated with survival (all p < 0.05). Focal slowing
was associated with death (OR 2.93; 95% CI 1.77–7.30) and a lower average voltage was associated with neurological
morbidity in survivors (p = 0.0032).
Conclusions: Despite substantial demographic and clinical heterogeneity between subjects in Malawi and Uganda
as well as different EEG readers at each site, EEG findings on admission predicted mortality and morbidity. For CM
clinical trials aimed at decreasing mortality or morbidity, EEG may be valuable for risk stratification and/or subject
selection.
Keywords: Malaria, Paediatrics, Africa, Malawi, Uganda
Background
Cerebral malaria (CM) is defined as an otherwise unexplained coma in a patient with malaria parasitaemia [1].
Despite improvements in anti-malarial treatment regimens, the mortality rate in tertiary care centres remains
15–25% and approximately one-third of survivors are
left with neurological sequelae at hospital discharge
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including developmental or behavioural abnormalities,
and epilepsy [2, 3]. Single-site studies have suggested
that admission electroencephalogram (EEG) may offer
important insights into both prognosis [4, 5] and the
pathophysiology of CM [2]. Several phase II and III
clinical trials aimed at improving survival and neurologic outcomes from CM are ongoing or have been
recently completed [6–9]. Future phase III clinical trials could potentially benefit from validation of a noninvasive biomarker that allows identification of children
at high risk of death. Such a marker might allow for
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subject enrichment during enrollment or stratification
of collected data.
EEG is not routinely available across Africa. Previously
published single-site case series have reported a number of abnormalities in the EEGs of children with CM
including diffuse slowing, atypical sleep elements (spindles and vertex waves), and epileptiform activity [5, 10,
11]. In a case series of 65 Kenyan children with CM, a
slower background frequency was significantly associated with an increased risk of death [5]. Burst-suppression was found in a higher proportion of children who
died compared to those who lived, but the numbers of
children with burst-suppression was small and the differences in proportions between outcome groups were not
statistically significantly different. A report from Malawi
identified a lack of variability and reactivity to painful
stimulation as a risk factor for mortality [12]. A recently
published study of acute magnetic resonance imaging
and EEG findings in 168 Malawian children with CM
determined that a slower background frequency was significantly associated with increased mortality risk [4]. No
multi-site studies of EEG in CM have been published.
The epidemiology of CM is rapidly evolving due to climate change and successful control programs resulting
in some regions with decreased disease burden, countered by other regions where incidence is constant or
increasing [1]. Definitive clinical trials aimed at decreasing malaria morbidity and mortality will likely require
multiple study sites both to assure access to adequate
numbers of eligible children as well as improve the generalizability of results. To explore the potential value of
EEG for subject selection or stratification in future clinical trials, admission EEG factors were compared between
the two study sites, and the associations of these factors
with death and neurodisability in Malawian and Ugandan children determined. This study’s goal was to identify
EEG factors associated with death or neurological disability that could potentially inform future clinical trials.
Identification of EEG changes associated with mortality
and morbidity that might allow further insight into the
underlying pathophysiology of death and disability in
children with CM were assessed.

Methods
Clinical and admission EEG data in consecutively admitted children with CM from Uganda and Malawi were
gathered. Mulago Hospital is a large (1600 bed) Ugandan
public tertiary care facility located in the country’s capital, Kampala. Queen Elizabeth Central Hospital (QECH)
is the largest public health care facility in Malawi and
located in the country’s commercial capital of Blantyre.
Both hospitals are home to independent long-standing studies of severe malaria pathogenesis and natural
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history. Children 6 months to 15 years old, admitted to
either Mulago or QECH with a clinical diagnosis of CM
(Blantyre coma score ≤ 2, Plasmodium falciparum on
peripheral blood smear, and no other known aetiology of
coma) between December 2008 and January 2012 were
eligible for inclusion. All children included in this substudy were recruited for comprehensive projects studying
CM pathogenesis and clinical epidemiology.
Nurse to patient ratios were high in both countries (one
nurse to two patients or occasionally 1:1)—substantially
higher than is the standard of routine care. In Malawi,
children were hospitalized on a paediatric research ward
dedicated to the study of children in coma, while in
Uganda they were admitted to the high acuity ward (paediatric intensive care unit) with dedicated study nurses.
EEGs were recorded within 12 h of admission at
both sites. All children were comatose (Blantyre Coma
Score ≤ 2) at the time of recording. Malawi used a Ceegraph digital machine (BioLogic/Natus, Pleasanton,
California) and Uganda an XLTEC 32 channel machine
(Natus Medical Corporation, Pleasanton, California).
EEG technicians used the international 10–20 system
for electrode placement. Recording duration was 30 min
or more, unless the patient became medically unstable
or was otherwise unable to tolerate the procedure. EEG
interpretations used for patient care were performed
during hospitalization by study and non-study personnel
to assess for non-convulsive status epilepticus or electrographic seizures. Research interpretations used for
this study were performed after hospital discharge by a
paediatric neurologist (DP, Uganda) or an epileptologist (GB and PK, Malawi) using Persyst Insight II (Persyst corporation, Prescott, Arizona). Interpreters were
blinded to the child’s outcome. Interpretations were
scored on a standardized form with predetermined definitions for each finding. These included: a determination
of average background frequency; average and maximal
voltages (excluding vertex sharp waves); the absence or
presence of spontaneous EEG variability; the absence or
presence of sleep spindles; the absence or presence of
vertex waves; a quantitation of the proportion of epochs
with sleep spindles (0, 1–25%, 26–50%, 51–75%, > 75%);
identification and characterization of epileptiform activity; and determination of EEG reactivity. EEG technicians
assessed reactivity by application of a painful stimulus
(usually a sternal rub) to determine if changes in frequency or amplitude occurred. Previous experience with
interpretation of EEGs in children with CM led us to
characterize two types of reactivity, paradoxical or normal. EEG interpreters defined paradoxical reactivity as
slowing in frequency or decrease in amplitude by more
than 50% that occurred after application of a painful
stimulus. Normal reactivity was defined as an increase in
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frequency or amplitude by more than 50% that occurred
after stimulation. An electrographic seizure was defined
as a rhythmic repetitive spike-wave discharge with an
electrical field that evolved in frequency, morphology, or
amplitude over at least 10 s. Although several children
had multiple EEGs performed during their hospital stay,
only the first EEG obtained was used in this analysis as
this would be the one most relevant for informing future
clinical trials.
During hospitalization, clinical seizures were treated
first with intravenous diazepam or intramuscular paraldehyde. If ictal phenomena were recurrent or prolonged,
phenobarbital was added. Breakthrough seizures on phenobarbital were treated by adding phenytoin. Clinical
complications were treated as they developed. Continuous EEG monitoring was not performed in either centre.
In the children who survived, outcome was determined
at hospital discharge by parent interview and a neurological exam; examinations were performed by physicians in Uganda and by a physician or clinical officer in
Malawi. Clinical officers are paramedical professionals
who undergo 3 years of technical training after secondary school. They are largely trained to use an algorithmic
approach to patient care for conditions commonly seen
in their region. They are not explicitly trained to conduct
a detailed neurologic assessment.
Children whose parents stated they were not back to
normal (new motor, cognitive, or behavioural abnormalities), or children found to have new neurological signs
on examination were classified as ‘alive with sequelae’.
Those with normal neurological exams and whose parents reported they were back to baseline were classified
as ‘normal’. Across institutions, there were no further
specific criteria to determine whether a child should be
classified as normal versus alive with sequelae.
Statistical analysis

Demographic factors, clinical characteristics and discharge outcomes of the study population were described
using means (and standard deviations) or proportions.
To evaluate differences between study site populations,
comparisons were made in continuous and categorical
EEG variables in Malawi and Uganda. Wilcoxon rank
sum tests were used for comparisons of continuous data.
Pearson’s Chi square tests were used for categorical data
where all cell counts were ≥ 5; Fisher’s exact tests were
used to analyse categorical data with cell counts less
than 5. Pooling data from Uganda and Malawi, univariate analyses of continuous EEG variables (e.g. frequency,
amplitude) in children of differing outcomes were compared using Wilcoxon rank sum tests. Categorical EEG
variables (e.g. asymmetry, reactivity, variability, presence or absence of electrographic seizures) in children of
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differing outcomes were compared using Pearson’s Chi
square or Fisher’s exact test, as appropriate. A two-sided
p < 0.05 was considered a statistically significant difference between groups.

Results
During the study period, 281 EEGs were performed
and analysed, 122 from Uganda and 159 from Malawi.
Tables 1 and 2 compare demographic, clinical, EEG and
outcomes data between the two sites. The Malawian population was comprised only of retinopathy positive children (versus 72.5% in Uganda) and were older (4.2 versus
3.7 years; p = 0.046), had a higher HIV prevalence (9.0
versus 2.8%; p = 0.042), and worse hyperlactataemia (7.4
versus 5.2 mmol/L; p < 0.001) on admission than Ugandan
children (Tables 1 and 2). In Uganda, 21 children (17.2%)
died and 44 of the 100 survivors (44.0%) had neurological sequelae at hospital discharge. (In one Ugandan survivor, the presence or absence of neurological sequelae was
unknown.) In Malawi, outcomes were better: 22 children
(13.8%) died, and 11.3% (16 of the 137 survivors) had neurological sequelae. There was no statistically significant
difference in the mortality rates between Malawi and
Uganda (p = 0.408). Rates of morbidity in survivors were
significantly higher in Uganda than Malawi (p = 0.002).
There were multiple statistically significant differences in admission EEGs when comparing Malawian and
Ugandan children (Tables 1 and 2). Average voltage was
lower and frequencies were slower in EEGs from Uganda
compared to those from Malawi. EEG variability, sleep
spindles, and vertex waves were significantly more common in Ugandan children, while EEGs from Malawian
children were more likely to show asymmetry. There
was no statistically significant difference in the proportion of children with electrographic seizures in the two
locations.
Tables 3 and 4 delineate the univariate analyses of
pooled EEG findings associated with mortality. Death was
associated with a lower average voltage (93.8 µV in survivors compared to 69.9 µV in those who died, p = 0.0032),
lower maximum voltage (210.6 µV in survivors compared
to 171.1 µV in those who died, p = 0.0089), and slower
dominant frequency (2.2 Hz in survivors compared to
1.8 Hz in those who died, p = 0.0030). Focal slowing
was associated with death (OR 2.93; 95% CI 1.77–7.30)
and reactivity with survival (OR for death 0.37; 95% CI
0.18–0.79).
A univariate analysis of pooled EEG findings associated
with neurological morbidity in survivors revealed that a
higher average voltage was associated with a normal neurological outcome in survivors (101.9 µV in those with a
normal outcome versus 70.1 µV in those with neurological sequelae, p < 0.0001) (Tables 5 and 6).
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Table 1 Comparison of clinical and EEG characteristics (continuous variables) between Malawian and Ugandan children
with cerebral malaria (value ± SD) (denominators vary due to missing data)
Variable

Uganda (N = 122)
N

Malawi (N = 159)
Mean ± SD
3.75 ± 1.95

N

Age (years)

122

Glucose (mg/dL)

119

Parasitemia (parasites/µL) (geometric
mean)

116

33,288.5

148

33,239.2

0.9961

Lactate (mmol/L)

117

5.2 (4.0)

159

7.4 (4.1)

< 0.0001

6.6 ± 3.4

159

Mean ± SD

p value
for difference

159

4.23 ± 2.27

0.0463

7.1 ± 3.7

0.8200

Blantyre Coma Score (n/N, %)

0.91

0

9 (7.4)

12 (7.6)

1

57 (46.7)

78 (49.1)

2

56 (45.9)

Average voltage (µV)

117

Maximum voltage (µV)

117

Dominant frequency (Hz)

115

65.77 ± 31.84

198.0 ± 73.16

1.93 ± 0.73

69 (43.4)
151
152
148

109.1 ± 55.17

< 0.0001

209.9 ± 88.62

0.3866

2.34 ± 1.09

0.0132

Table 2 Comparison of clinical and EEG characteristics (categorical variables) between Malawian and Ugandan children
with cerebral malaria (denominators vary due to missing data)
Variable

Uganda (n/N, %)

Malawi (n/N, %)

p value
for difference

Retinopathy positive

87/120 (72.5)

159/159 (100)

–

3/109 (2.8)

13/144 (9.0)

0.0423

Variability (% with)

73/119 (61.3)

78/159 (49.1)

0.0418

Asymmetry (% with)

15/122 (12.3)

49/159 (30.8)

0.0002

9/122 (7.4)

22/159 (13.8)

0.0867

Spindles (% with)

71/116 (61.2)

65/159 (40.9)

0.0009

Vertex sharp waves (% with)

56/118 (47.5)

39/159 (25.0)

< 0.0001

Slowing location (% focal)

5/117 (4.2)

19/159 (11.9)

0.0240

Normal reactivity (% with increase in voltage and/or frequency with stimulus)

4/113 (3.5)

41/153 (26.8)

< 0.0001

40/113 (35.4)

27/153 (17.6)

HIV reactivity

Electrographic seizures (% with)

Paradoxical reactivity (% with decrease in voltage and/or frequency with
stimulus)

Discussion
Despite the substantial noise of demographic and clinical
heterogeneity between subjects in Malawi and Uganda as
well as different EEG readers at each site, there is a clear
signal that EEG findings on admission predict mortality
and morbidity.
Admission EEG findings in children with CM from
Uganda differ from those recorded in Malawi. Possible explanations for these differences may be specific to
EEG (study technique, interpreter effect), intrinsic to the
nature of any multi-centre study (studies obtained at different time points, different inclusion criteria) or could
represent true differences between the Malawian and
Ugandan paediatric CM populations.
EEG interpretation is a subjective process with no currently available tools for objective, reliable quantification
of frequency, voltage, or any of the variables captured

in this study. Although automated tools are available to
aid interpretation, these are sensitive to artifact, creating
both false positive and negative findings, when compared
to human interpretation as the gold standard. Three
interpreters reviewed the EEGs included here, which
likely introduced variability into interpretations. Interrater correlation between EEG variables in often modest
[13], but relying on a single reader limits external generalizability [14]. The imperative to improve EEG interrater reliability in the identification of triphasic waves,
hypsarrhythmia and sleep architecture has recently
resulted in efforts aimed at developing more standardized terminology and/or additional reader training for
the identification of specific findings [15–18]. If EEG is to
be used for stratification and/or risk adjustment in multisite clinical trials of CM, improved standardization and/
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Table 3 Univariate analysis: Comparison of continuous clinical and EEG variables by outcome (mortality) (mean ± SD)
Country

Clinical or EEG variable

Alive (N = 101)

Died (N = 21)

p value

Uganda

Age (years)

3.8 ± 1.9

3.6 ± 2.1

0.77

30,315.4 (21.9)

53,669.7 (6.5)

0.3463

Glucose (mg/dL)
Parasitemia (parasites/µL) [geometric mean
(coefficient of variation)]
Lactate (mmol/L)
Average voltage (µV)
Maximum voltage (µV)
Dominant frequency (Hz)
Country

Clinical or EEG variable

Malawi

Age (years)
Glucose (mg/dL)
Parasitemia (parasites/µL) [geometric mean
(coefficient of variation)]
Lactate (mmol/L)
Average voltage (µV)
Maximum voltage (µV)
Dominant frequency (Hz)

Country

Clinical or EEG variable

Uganda + Malawi

Age (years)
Glucose (mg/dL)
Parasitemia (parasites/µL) [geometric mean
(coefficient of variation)]
Lactate (mmol/L)
Average voltage (µV)
Maximum voltage (µV)
Dominant frequency (Hz)

or development of validated sensitive and specific EEG
interpretation software will be needed.
Despite these challenges, it is possible that the differences seen in admission EEGs between Malawian and
Ugandan children represent intrinsic electrophysiological
differences between populations. In terms of pathophysiological insights, many of the EEG findings described
in this study are seen in other aetiologies of paediatric
coma. EEG findings in children with non-malarial central
nervous system infections are considered non-specific
as to aetiology (e.g. viral versus bacterial) and consist of
generalized delta waves [19], as was seen in these study
subjects. This pattern implies that large areas of subcortical white matter are functionally abnormal [20]. Generalized slowing is seen more commonly in disorders
primarily affecting white matter [21].
In a previous study of 201 children in coma in Italy, 26
of 77 children with central nervous system bacterial or
viral infections had convulsions, though the authors did
not clarify whether seizure activity was clinical, electrographic, or both [19]. Clinical seizures are very common

6.8 ± 3.3

4.9 ± 3.9

68.9 ± 31.9

206.3 ± 71.0

5.6 ± 3.6

6.7 ± 4.1

50.5 ± 27.4

0.2622

0.0467
0.018

158.0 ± 71.9

0.007

Died (N = 22)

p value

4.3 ± 2.3

4.1 ± 2.2

0.70

31,053.5 (25.4)

50,153.1 (13.6)

0.4189

2.0 ± 0.7

1.6 ± 0.9

Alive (N = 137)

7.1 ± 3.6

7.2 ± 4.1

112.2 ± 54.3

213.8 ± 88.4

7.4 ± 4.1

8.6 ± 3.8

89.3 ± 58.2

0.02

0.8675

0.0827
0.08

184.3 ± 88.2

0.17

Died (N = 43)

p value

4.0 ± 2.1

3.8 ± 2.1

0.3459

30,731.7 (23.5)

51,793.8 (9.0)

0.2168

2.4 ± 1.1

1.9 ± 0.9

Alive (N = 238)

7.0 ± 3.5

6.2 ± 4.2

93.8 ± 50.8

210.6 ± 81.4

2.2 ± 1.0

6.5 ± 4.0

7.7 ± 4.0

69.9 ± 49.0

171.1 ± 80.6

1.8 ± 0.9

0.05

0.5049

0.0170
0.0032
0.0089
0.0030

in CM. In this study, non-continuous electrographic seizures captured on a 30 min EEG were documented in
only 11.0% of subjects and were not associated with mortality or morbidity on pooled univariate analysis.
This study has several limitations. Continuous EEG
monitoring was not performed, which likely led to a
lack of sensitivity for ascertaining transient events. In
paediatric traumatic brain injury, subclinical electrographic seizures are common, and the combination of
clinical and electrographic seizures may occur in up to
77.3% of patients [14]. Studies of comatose children in
paediatric intensive care units without restriction by
coma aetiology reveal a 7% risk of subclinical electrographic seizures [22], a proportion similar to that seen
in this study’s subjects. It is not possible to know if continuous EEG sampling would have modified the associations found here.
The analysis of EEG factors associated with neurological morbidity was complicated by a non-standard
definition of this outcome across sites. For example, children with mild ataxia that was resolving were coded as
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Table 4 Comparison of categorical demographic and EEG variables by outcome (mortality) (OR, 95% CI)
Country

Uganda

Clinical or EEG variable

Children
with variable who
were alive
(N, %)

Total N (122)

101

21

Retinopathy positive

71 (70.3)

16 (73.2)

HIV reactivity

3 (3.0)

0 (0.0)

p value

1.63

0.41

0.5, 5.3

Variability

62 (61.4)

11 (52.4)

0.64

0.25, 1.65

0.35

13 (12.9)

2 (9.5)

0.71

0.15, 3.42

0.67

Electrographic seizures (present)

8 (7.9)

1 (4.8)

0.58

0.07, 4.9

0.62

Spindles (present)

60 (59.4)

11 (52.4)

0.64

0.25, 1.66

0.36

Vertex sharp waves

47 (46.5)

9 (42.9)

0.79

0.31, 2.07

0.64

Focal slowing

3 (2.9)

3 (14.3)

5.27

0.98, 28.3

0.052

Reactivity (normal + paradoxical)

40 (39.6)

4 (19.1)

0.306

0.09, 0.98

0.046

37 (36.6)

3 (14.3)

1.02

0.09, 10.46

0.55

1 (4.76)

0.25

0.07, 0.91

0.09

Paradoxical reactivity (decrease in voltage and/or 3 (2.97)
frequency with stimulus)
Total N (159)

137

22

Retinopathy positive

137 (100)

22 (100)

HIV reactivity

12 (9.7)

1 (5.0)

0.49

0.06, 4.0

0.5065

Variability

71 (51.8)

7 (31.8)

0.43

0.17, 1.13

0.087

Asymmetry

40 (29.2)

9 (40.9)

1.68

0.66, 4.23

0.27

Electrographic seizures present

16 (11.7)

6 (27.3)

2.84

0.97, 8.3

0.06

Spindles present

58 (42.3)

7 (31.8)

0.64

0.24, 1.66

0.35

Vertex sharp waves

37 (27.0)

2 (9.1)

0.27

0.06, 1.21

0.09

Focal slowing (focal versus gen)

14 (10.2)

5 (22.7)

2.58

0.83, 8.08

0.10

Reactivity (normal + paradoxical)

62 (45.3)

6 (27.3)

0.45

0.17, 1.2

0.12

37 (27.0)

4 (18.2)

0.51

0.16, 1.63

0.77

2 (9.1)

0.37

0.08, 1.75

0.42

Normal reactivity (increase in voltage and/or
frequency with stimulus)

Paradoxical reactivity (decrease in voltage and/or 25 (18.2)
frequency with stimulus)
Uganda + Malawi Total N (281)

238

43

Retinopathy positive

208 (87.4)

38 (88.4)

1.32

0.44,3.98

0.62

HIV reactivity

15 (6.7)

1 (3.5)

0.49

0.06, 3.91

0.5072

Variability

133 (55.9)

18 (41.9)

0.552

0.29,1.07

0.077

Asymmetry

53 (22.3)

11 (25.6)

1.20

0.57,2.54

0.634

Electrographic seizures present

24 (10.1)

7 (16.3)

1.73

0.69,4.32

0.24

Spindles present

118 (49.6)

18 (41.9)

0.696

0.36,1.34

0.28

Vertex sharp waves

84 (35.3)

11 (25.6)

0.614

0.29,1.28

0.19

Focal slowing

17 (7.1)

8 (18.6)

2.93

1.76,7.3

0.02

Reactivity (normal + paradoxical)

102 (42.9)

10 (23.3)

0.374

0.18,0.79

0.010

40 (16.8)

5 (11.6)

0.477

0.17,1.31

0.79

Paradoxical reactivity (decrease in voltage and/or 62 (26.1)
frequency with stimulus)

5 (11.6)

0.308

0.11,0.83

0.13

Reactivity (increase in voltage and/or frequency
with stimulus)

a

Odds ratioa 95%
confidence
interval

Asymmetry

Normal reactivity (increase in voltage and/or
frequency with stimulus)

Malawi

Children
with variable
who died
(N, %)

Odds of death of children having the EEG feature divided by the odds of death of children without the EEG feature

“normal” in Malawi, but “abnormal” in Uganda. Future
studies comparing EEG factors associated with neurological morbidity should standardize criteria to define

neurosequelae. Children were classified as having neurological morbidity at discharge. Since neurological
sequelae at discharge may clear over time, or epilepsy
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Table 5 Univariate analysis: comparison of continuous clinical and EEG variables by outcome (neurological morbidity
in survivors) (mean ± SD)
Country

Clinical or EEG variable

Alive and normal (N = 56)

Alive with sequelae
(N = 44)

p value

Uganda

Age (years)

3.8 ± 1.7

3.8 ± 2.2

0.5312

31,931.6 (23.3)

Glucose (mg/dL)
Parasitemia (parasites/µL) [geometric mean
(coefficient of variation)]
Lactate (mmol/L)
Average voltage (µV)
Maximum voltage (µV)
Dominant frequency (Hz)
Country
Malawi

Clinical or EEG variable
Age (years)
Glucose (mg/dL)
Parasitemia (parasites/µL) [geometric mean
(coefficient of variation)]
Lactate (mmol/L)
Average voltage (µV)
Maximum voltage (µV)
Dominant frequency (Hz)

7.2 ± 3.3

6.4 ± 3.4

0.1376

31,434.9 (18.7)

0.9755

4.6 ± 3.7

5.3 ± 4.2

0.4449

213.8 ± 71.2

199.1 ± 70.3

0.3809

Alive with sequelae
(N = 16)

p value

74.0 ± 32.1
2.0 ± 0.7

Alive and normal
(N = 121)
4.3 ± 2.3

63.6 ± 30.8

0.0723

2.0 ± 0.6

0.9210

3.5 ± 1.9

6.9 ± 2.9

8.3 ± 7.0

0.6468

73,486.0 (10.4)

0.1988

7.0 ± 4.0

8.4 ± 4.8

0.3023

217.4 ± 86.3

180.0 ± 103.1

0.1185
p value

28,148.2 (27.4)

114.5 ± 54.2
2.4 ± 1.1

91.5 ± 52.6
2.1 ± 1.3

0.2178
0.1550

Country

Clinical or EEG variable

Alive and normal
(N = 177)

Alive with sequelae
(N = 60)

Uganda + Malawi

Age (years)

4.2 ± 2.2

3.7 ± 2.1

0.0723

29,312.6 (25.57)

38,422.1 (16.66)

0.4876

Glucose (mg/dL)
Parasitemia (parasites/µL) [geometric mean
(coefficient of variation)]
Lactate (mmol/L)
Average voltage (µV)
Maximum voltage (µV)
Dominant frequency (Hz)

may appear after a delay of months, misclassification
may have occurred. Since post-CM epilepsy can develop
months after hospitalization, this study could not identify acute EEG characteristics that are predictors of later
developing epilepsy. Future studies should consider
ascertainment of admission EEG factors associated with
long-term neurological disability. In younger patients,
post-CM developmental disabilities may be difficult to
detect and only become clear as the patient ages, when
the survivor’s developmental milestones diverge from
those of their unaffected peer group. Identification of
EEG changes in children at higher risk of a long-term
adverse outcome may allow focus of limited resources
(physiotherapy, palliative care) to those at highest risk.
Retinopathy negative children were not represented
in Malawi, as children from this site were enrolled in a
parent study whose primary interest was retinopathy

7.0 ± 3.0

6.9 ± 4.7

6.3 ± 4.0

6.1 ± 4.5

216.3 ± 81.8

194.6 ± 78.5

101.9 ± 51.9
2.3 ± 1.0

70.1 ± 38.4
2.0 ± 0.8

0.1999

0.5321
< 0.0001
0.0943
0.0524

positive CM. Since one-third of children with clinical CM
are retinopathy negative, the population from Malawi
may not be representative of the clinical spectrum of
children with this illness.
Identification of EEG factors associated with death
and long-term adverse neurological outcome may allow
insights into whether these outcomes share a common
pathophysiology. Since seizures are considered primarily a gray matter-based abnormality, while slowing and
decreased amplitudes are primary due abnormalities in
the thalamo-cortical circuits (white matter based), it is
possible that interventions successful in reducing rates of
one outcome (mortality) may not lead to a change in the
proportion of children with the other endpoint (e.g. an
increase in the proportion of survivors with neurological
disabilities).
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Table 6 Comparison of categorical demographic and EEG variables by outcome (neurological morbidity in survivors)
(OR, 95% CI)
Country

Clinical or EEG variable

Uganda

Total N (101)
Retinopathy positive
HIV reactivity
Variability

38 (69.1)

95%
confidence
interval

p value

1.19

0.49, 2.86

0.6930

0
34 (64.2)

0.98

0.43, 2.25

0.9581

4 (9.1)

9 (16.1)

0.52

0.15, 1.83

0.3089

Electrographic seizures
(present)

3 (6.8)

5 (8.9)

0.75

0.17, 3.31

0.7002

Spindles (present)

26 (61.9)

34 (64.2)

0.91

0.39, 2.10

Vertex sharp waves

22 (51.2)

25 (47.2)

1.17

0.52, 2.63

0.6972

0

2 (3.8)

Reactivity (normal + paradoxi‑
cal)

15 (37.5)

25 (49.0)

0.62

0.27, 1.45

0.2730

Normal reactivity (increase in
voltage and/or frequency
with stimulus)

2 (5.0)

1 (1.9)

2.08

0.18, 24.40

0.4128

13 (32.5)

24 (47.1)

0.56

0.24, 1.35

0.1895

Total N (137)
HIV reactivity

1 (7.1)

11 (10.0)

0.69

0.08, 5.81

0.7347

Variability

7 (43.8)

64 (52.9)

0.69

0.24, 1.98

0.4932

Asymmetry

7 (43.8)

33 (27.3)

2.07

0.72, 6.02

0.1797

Electrographic seizures present

6 (37.5)

10 (8.3)

6.7

2.0, 22.1

0.002

Spindles present

5 (31.3)

53 (43.8)

0.58

0.19, 1.78

0.3438

Vertex sharp waves

1 (6.3)

36 (29.8)

0.16

0.02, 1.24

0.0788

Focal slowing (focal versus gen)

4 (25.0)

10 (8.3)

3.7

1.01, 13.6

0.0491

Reactivity (normal + paradoxi‑
cal)

6 (37.5)

56 (48.3)

0.64

0.22, 1.89

0.4209

Normal Reactivity (increase in
voltage and/or frequency
with stimulus)

5 (31.3)

32 (27.6)

0.94

0.29, 2.98

0.3837

Paradoxical reactivity (decrease
in voltage and/or frequency
with stimulus)

1 (6.3)

24 (20.7)

0.25

0.03, 2.06

0.2025

48 (80.0)

159 (90.3)

0.43

0.19, 0.96

0.0390

4 (7.0)

11 (6.6)

1.06

0.33, 3.48

0.9190

Total N (281)
Retinopathy positive
HIV reactivity
Variability

35 (58.3)

98 (56.3)

1.09

0.59, 1.97

0.7862

Asymmetry

11 (18.3)

42 (23.7)

0.72

0.34, 1.51

0.3875

Electrographic seizures present

9 (15.0)

15 (8.5)

1.91

0.79, 4.62

0.1529

Spindles present

31 (53.5)

87 (50.0)

1.15

0.63, 2.08

0.6493

Vertex sharp waves

23 (38.9)

61 (35.1)

1.18

0.64, 2.18

0.5875

4 (6.8)

12 (6.9)

0.98

0.30, 3.17

0.9756

Reactivity (normal + paradoxi‑
cal)

21 (37.5)

81 (48.5)

0.64

0.34, 1.19

0.1543

Reactivity (increase in voltage
and/or frequency with
stimulus)

7 (12.5)

33 (19.8)

0.52

0.21, 1.29

0.2856

14 (25.0)

48 (28.7)

0.72

0.35, 1.46

0.9846

Focal slowing

Paradoxical reactivity (decrease
in voltage and/or frequency
with stimulus)
a

3 (6.9)

Odds ratioa

28 (63.6)

Paradoxical reactivity (decrease
in voltage and/or frequency
with stimulus)

Uganda + Malawi

32 (72.7)

Children with variable who
were alive without sequelae
(N, %)

Asymmetry

Focal slowing

Malawi

Children with variable who
were alive with sequelae
(N, %)

Odds of disability of children having the EEG feature divided by the odds of disability of children without the EEG feature
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Conclusions
In children with CM, death is associated with patterns
on admission EEG. Findings increasing the risk of death
include a lower average voltage, lower maximum voltage,
slower dominant frequencies, focal slowing, and a lack
of reactivity. For CM clinical trials aimed at decreasing
mortality, EEG may be valuable for risk stratification and/
or subject selection.
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